ONWARD Medical Receives Grant for Groundbreaking Study
ONWARD Medical N.V. (Euronext: ONWD) recently shared some exciting news. The innovative medical technology company is set to advance its groundbreaking spinal cord stimulation therapies, which aim to help those with spinal cord injuries (SCI) regain movement and independence. Thanks to a grant from the Christopher & Dana Reeve Foundation, ONWARD is expanding its early clinical feasibility study that focuses on a brain-computer interface (BCI) designed to restore hand and arm function following injury.
Clinical Trials and Partnerships
This promising study, which has already received backing from the European Innovation Council, is gaining momentum through collaboration with .NeuroRestore, a research initiative that includes the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). The new funding of $1.1 million will allow the implantation of the ONWARD ARC-BCI System in up to four more participants.
A Breakthrough in Movement Restoration
According to ONWARD Medical’s CEO, Dave Marver, while many companies are exploring BCI technology for computer interfaces, ONWARD is leading the way in enhancing movement restoration for individuals with SCI. The support from the Reeve Foundation is vital for advancing their important clinical research.
Research Impact and Future Opportunities
Dr. Marco Baptista, Chief Scientific Officer at the Christopher & Dana Reeve Foundation, expressed enthusiasm about this partnership, highlighting their shared goal of accelerating scientific breakthroughs that meet the urgent needs of those living with SCI.
Understanding the ARC-BCI System
The ARC-BCI System represents an exciting fusion of advanced technology. It combines the investigational WIMAGINE BCI with ONWARD ARC-IM Therapy, aiming to provide patients with thought-driven control over their movements, effectively acting as a DigitalBridge™. The WIMAGINE has demonstrated impressive safety data over the years and shows promise in enhancing patients' voluntary movement capabilities.
Regulatory Recognition and Innovative Solutions
Earlier this year, ONWARD Medical proudly announced its acceptance into the FDA’s Total Product Lifecycle Advisory Program (TAP) for its ARC-BCI platform, which has also received Breakthrough Device Designation (BDD). These recognitions indicate significant progress in bringing innovative therapies to the market.
Commitment to Excellence in SCI Care
ONWARD Medical’s commitment to restoring function for individuals with SCI is evident in its extensive research and development efforts. Their pioneering ARC Therapy™ has garnered multiple Breakthrough Device Designations from the FDA, underscoring the company’s dedication to scientific excellence and patient care. Through the ARC-BCI platform, ONWARD is exploring new applications to address mobility challenges and the potential for improved gait in various conditions, including Parkinson's disease.
About ONWARD Medical
Headquartered in Eindhoven, ONWARD Medical operates a Science and Engineering Center in Lausanne, Switzerland, and has a US office in Boston. The company continues to push the boundaries of medical technology, striving to ensure that innovative spinal cord therapies lead to better outcomes for patients around the globe. As a publicly traded company on Euronext, their ticker symbol ONWD reflects their growth journey in this impactful area of healthcare.
Frequently Asked Questions
What is the purpose of the grant received by ONWARD Medical?
The grant is intended to expand an early clinical feasibility study that investigates the use of a brain-computer interface to restore movement for individuals with spinal cord injuries.
Who are ONWARD Medical's partners in this research?
ONWARD Medical collaborates with the Christopher & Dana Reeve Foundation and .NeuroRestore, which includes the Swiss Federal Institute of Technology and Lausanne University Hospital.
What does the ARC-BCI System offer?
The ARC-BCI System integrates targeted spinal cord stimulation with brain-computer interface technology to enable thought-driven movement restoration for patients.
How is ONWARD Medical advancing its therapy technologies?
ONWARD Medical is involved in FDA programs and has received multiple Breakthrough Device Designations, highlighting its commitment to innovative healthcare solutions.
Where is ONWARD Medical headquartered?
ONWARD Medical is headquartered in Eindhoven, the Netherlands, with additional facilities in Switzerland and the United States.
